Dermatology Lab · Cure for X

Cure for Nonsyndromic congenital nail disorder 4

PatSci's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for nonsyndromic congenital nail disorder 4 — screening already-approved drugs against its 2-gene Open Targets disease module to file a DAO-owned patent. Research is fast; the filing path is funded in milestone stages.

Disease module2 genesLead labDermatology

All cures

DermatologyDOID:0050643$PatSciDerma

The science

Disease moduleNonsyndromic congenital nail disorder 4 maps to a 2-gene Open Targets module — the target space PatSci's AI scientist screens approved drugs against.

PatSci.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces PatSci.ai's repurposing hypotheses.

Repurposing thesisScreening already-approved drugs against this module — then filing a new-use patent on the most promising candidate. Known safety profiles make the path faster and cheaper than de-novo discovery.

The patent path

Priority€50K

Candidate research + dossier + UK patent deposit (priority date, prior-art scan).Month 0 · proof: UKIPO application number + on-chain hash

Validation€150K

In-vitro biological validation at a contract research org (CRO).Months 1–10 · proof: CRO contract + in-vitro report

PCT Global€600K

International PCT filing across 150+ countries.by Month 12 · proof: PCT application number

National€200K

National / regional phases (EU, US, CN).by Month 30 · proof: National grant confirmations

PatSci is a research and patent-filing project, not medical advice and not a treatment. "Cure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund patent work — it is not an investment, and confers no yield, royalty, equity or patent ownership. Patents are owned by the PatSci.ai DAO Patent Estate.